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Abstract
Background: Arsenic exposure is an important public health issue worldwide. Dose-response relationship between
arsenic exposure and risk of urothelial carcinoma (UC) is consistently observed. Inorganic arsenic is methylated to
form the metabolites monomethylarsonic acid and dimethylarsinic acid while ingested. Variations in capacity of
xenobiotic detoxification and arsenic methylation might explain individual variation in susceptibility to arsenic-
induced cancers.
Methods: To estimate individual susceptibility to arsenic-induced UC, 764 DNA specimens from our long-term
follow-up cohort in Southwestern Taiwan were used and the genetic polymorphisms in GSTM1, GSTT1, GSTP1 and
arsenic methylation enzymes including GSTO1 and GSTO2 were genotyped.
Results: The GSTT1 null was marginally associated with increased urothelial carcinoma (UC) risk (HR, 1.91, 95% CI,
1.00-3.65), while the association was not observed for other GSTs. Among the subjects with cumulative arsenic
exposure (CAE) ≥ 20 mg/L*year, the GSTT1 null genotype conferred a significantly increased cancer risk (RR, 3.25,
95% CI, 1.20-8.80). The gene-environment interaction between the GSTT1 and high arsenic exposure with respect
to cancer risk was statistically significant (multiplicative model, p = 0.0151) and etiologic fraction was as high as
0.86 (95% CI, 0.51-1.22). The genetic effects of GSTO1/GSTO2 were largely confined to high arsenic level (CAE ≥ 20).
Diplotype analysis showed that among subjects exposed to high levels of arsenic, the AGG/AGG variant of GSTO1
Ala140Asp, GSTO2 5’UTR (-183)A/G, and GSTO2 Asn142Asp was associated with an increased cancer risk (HRs, 4.91,
95% CI, 1.02-23.74) when compared to the all-wildtype reference, respectively.
Conclusions: The GSTs do not play a critical role in arsenic-induced urothelial carcinogenesis. The genetic effects
of GSTT1 and GSTO1 on arsenic-induced urothelial carcinogenesis are largely confined to very high exposure level.
Background
Arsenic (As) exposure is an important public health
issue worldwide and more than 100 million people are
exposed to arsenic-contaminated water supplies that
contain arsenic at a level higher than the internation-
ally-accepted standard (10 μg/L in Taiwan and USA).
Chronic arsenic ingestion induces adverse health effects
in humans, including black-foot disease [1,2], ischemic
heart disease [3,4], hypertension [5], diabetes mellitus
[6], cerebrovascular and microvascular diseases [7,8] and
various cancers [9,10]. A strong association of arsenic
exposure with an increased incidence of bladder cancer
has been observed in the southwest (high-exposure area)
and northeast (moderate-exposure area) regions of Tai-
wan [11,12]. Even with a relatively low exposure level,
the association of arsenic with bladder cancer risk has
also been observed in Finnish study [13]. Nonetheless,
among relatively homogeneously exposed people, the
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there is a marked variation in susceptibility among indi-
viduals. Nutritional status, ethnicity, an early age of
exposure and variations in arsenic biotransformation are
all potentially responsible for differences in individual
susceptibility to arsenic-induced carcinogenesis.
Most mammals, including humans, metabolize inor-
ganic arsenic via arsenic methylation to a range of dif-
ferent metabolites that haved i f f e r e n tt o x i cp o t e n c i e s
[14,15]. The classic methylation pathway involves reduc-
tion and methylation reactions via one-carbon metabo-
lism. Pentavalent arsenicals such as arsenate As(V) or
monomethylarsonic acid [MMA(V)] can be reduced to
trivalent arsenite [As(III)] or monomethylarsinic acid
[MMA(III)] respectively; and then methyl groups from
S-adeno methionine (SAM) are used for further methy-
lation to form the metabolites monomethylarsonic acid
[MMA(V)] and dimethylarsinic acid [DMA(V)]. Varia-
tion in the production and excretion of these arsenic
metabolites could explain individual variation in arsenic
toxicity [16]. Recent studies have revealed that arsenic
metabolic capacity may be an important risk-modifying
factor for arsenic-induced health effects. Inefficient
methylation of arsenic has been documented to be a sig-
nificant modifier for arsenic-induced skin lesions and
cancers, bladder cancer, peripheral arterial disease,
hypertension and carotid atherosclerosis [17-21].
The efficiency of arsenic methylation can be influ-
enced by genetic polymorphisms within individuals
[22,23]. Glutathione S-transferase omega (GSTO) and
arsenic (III) methyltransferase (AS3MT, or CYT19) are
involved in classic arsenic methylation in a variety of
animals including humans [24-26]. The GSTOs, includ-
ing GSTO1 and GSTO2, can catalyze the reduction of
MMA(V) to MMA(III), which is thought to be the rate-
limiting step of arsenic methylation in humans [27]. The
relationship between the GSTOs and arsenic metabo-
lism has been explored to test if GSTO polymorphisms
can explain variation in arsenic methylation capacity as
well as variation in individual susceptibility to arsenic
exposure. Most studies have not shown a significant
association of this gene with extreme urinary profiles
[28-30]. However, a recent study in Taiwan showed that
the GSTO2 Asn142Asp (N142D) homo-variant was
associated with an increased iAs% [31]. A study of a
northern Mexican population also suggested that there
is an association between GSTO1 E155del and an
increased percentage of inorganic arsenic, either As
III or
As
V [32]. The association of GSTOs with As-induced
health effects has also been examined in several arsenia-
sis areas. The polymorphisms in GSTOs could be a sig-
nificant modifier for arsenic-induced skin lesions and
urothelial carcinoma (UC) [20,33]. For the purpose to
further clarify the effect of GSTOs as well as other GST
family members on arsenic-induced urinary cancers, we
monitored a cohort of 764 subjects established in South-
west Taiwan in 1988 and single nucleotide polymorph-
isms (SNPs) genotyping was performed. The association
o fG S T M 1 ,G S T T 1 ,G S T P 1 ,G S T O 1a n dG S T O 2w i t h
UC risk was examined. In addition, the joint effect of
such genes with levels of arsenic exposure on cancer
risk was also examined.
Materials and methods
Study cohort
Putai township, located on the southwestern coast of
Taiwan, is a township where blackfoot disease (BFD) is
endemic and it has an overall BFD prevalence of about
2.2/1000. The residents in Putai consumed artesian well
water (100-300 meters deep) for more than 50 years.
Three villages, Homei, Fuhsin, and Hsinming in Putai
Township have the highest BFD prevalences at 13.6, 9.6,
and 10.3/1000, respectively [34]. These villages were
selected as the study area. The median arsenic concen-
trations of the artesian well water ranged from 0.70
ppm to 0.93 ppm in the study area. The residents
stopped artesian water consumption in the 1970s when
a tap water supply system was implemented. From a
total of 2258 residents aged 30 or older who were regis-
tered in the study area, only 1571 who lived at least 5
days a week in the village were recruited into the study
in 1988. Twenty-five subjects were excluded from the
study either due to previous cancer history or incom-
plete personal identification information, and finally a
total of 1546 subjects were recruited for the study. All
the subjects were of the same Ming-Nang ethnicity.
Between 1989 and 1996, about 1081 study subjects
underwent six community health examinations. At this
time, biological specimens were collected including
urine, blood buffy coat, hair, and nails. The buffy coat
samples were stored at -80°C for DNA extraction at a
later date. About 30% subjects refused to give the blood
samples or had inadequate DNA samples. There were
no differences in characteristics between the subjects
with and without blood samples based on age, gender,
educational level and smoking status. A total of 764
(71%) adequate lymphocyte DNA samples were available
for SNP analysis.
A standardized personal interview based on a struc-
tured questionnaire was carried out in 1988 to collect
information on risk factors including sociodemographic
characteristics, lifetime residential and occupational his-
tories, drinking water supply, cigarette smoking, alcohol
drinking, as well as personal and family history of dis-
ease. Detailed histories of residency and duration of
drinking artesian well water were used to derive a
cumulative arsenic exposure. The cumulative arsenic
exposure (CAE) of each subject was defined as Σ(Ci ×
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water of the ith village the subject had lived and Di=
the duration (years) of drinking artesian water in the ith
village [35]. CAE was calculated only for those subjects
for whom there was complete information on arsenic
exposure due to drinking artesian well water throughout
his or her lifetime. The CAE was set at “0” when the
subjects consumed water with arsenic concentrations
equal or less than 10 μg/L.
Cancer Incidence
Individuals’ unique national identification was used to
link with the national cancer registry profile in Taiwan
to identify the cancer status of each cohort subject. The
cancer registry system was implemented in 1978 and
the complete information for cancer was updated regu-
larly for the whole Taiwan population.
SNP Genotyping
The GSTM1 and GSTT1 primer pairs (table 1) were
mixed with b-globulin primer (5’-CAA CTT CAT CCA
CGT TCA CC-3’ and 5’-GAA GAG CCA AGG ACA
GGT AC-3’) in a multiplex polymerase chain reaction
(PCR). PCR was performed in a total volume of 100 μL,
containing 10 μL of genomic DNA (50-100 ng), 400 ng
of each of the above primers, and 5 units of Taq poly-
merase (SuperTag, Protech, Taiwan). The reaction was
incubated at 94°C for 4 min and subjected to 35 cycles
of 94°C for 60 s, 55°C for 60 s and 72°C for 60 s, then a
final 72°C-extension for 10 min. Next, 10-μL PCR ali-
quots were electrophoresed on 2% agarose gels and
were stained with ethidium bromide. The internal stan-
dard fragment of a-globulin was 268-bp in length,
whereas the amplified gene products of GSTM1 and
GSTT1 were 215 bp and 480 bp, respectively.
Determination of genotype at the GSTP1 locus by the
PCR-restriction fragment length polymorphism (RFLP)
method and the primers for PCR are 5’-ACC CCA
GGG CTC TAT GGG AA-3’ and 5’-CAG GTT GTA
GTC AGC GAA G-3’. The reaction was incubated at
94°C for 4 min and subjected to 35 cycles of 94°C for
30 s, 60°C for 30 s, 72°C for 30 s, and a final 72°C-
extension for 5 min. The PCR products were digested
with 5 U of Alw261 (New England Biolabs, Beverly,
MA) and the products were separated on 3% agarose
gels. The GSTP1 I105V A/G polymorphisms were clas-
sified as homozygous A/A (major allele), heterozygous
for A/G, or homozygous for G/G (minor allele).
Real-time PCR: Genotyping for polymorphisms in
GSTO1 A140D, K208E, E155del and GSTO2 5’UTR
(-183) A/G and N142D was performed using real-time
PCR. For each of the SNPs, primer-probe sets were
made using the Applied Biosystems design service (Fos-
ter City, California). Two fluorogenic minor groove bin-
der probes were designed with different fluorescent dyes
to allow single-tube genotyping. The primers for SNP
genotyping are listed in table 1. Real-time PCR was per-
formed using 2.5 μL of TaqMan 2× universal master
mix (Applied Biosystems, Foster City, CA), 0.05 μLo f
40× primer-probe, 0.45 μL of RNase- and DNase-free
water, and 2 μL of sample DNA, in a total volume of 5
μL per single tube reaction. DNase-free water served as
the nontemplate control and DNA of known genotype
was used as a positive control; both were included in
each assay run. Assay conditions were 2 min at 50°C, 10
min at 95°C, and 40 cycles of PCR at 95°C for 15 s and
Table 1 The description of SNPs of arsenic-metabolized enzyme and the primers used for realtime PCR
Enzyme Base change Amino acid
change
Variant allele
frequency
Accession
number
Primer pairs
GSTM1 Gene
deletion
No protein 0.5749 5’-GAA CTC CCT GAA AAG CTA AAG C-3’ &5 ’-GTT GGG CTC AAA
TAT ACG GTC G-3’
GSTT1 Gene
deletion
No protein 0.4966 5’-TTC CTT ACT GGT CCT CAC ATC TC-3’ &5 ’-TCA CCG GAT CAT
GGC CAG CA-3’
GSTP1 Exon 5
A®G
Ile105Val
(I105V)
0.2256 rs1695 5’-ACC CCA GGG CTC TAT GGG AA-3’ &5 ’-CAG GTT GTA GTC
AGC GAA G-3’
GSTO1 Exon 4 C®A Ala140Asp
(A140D)
0.1660 rs4925 C_11309430_30
GSTO1 Exon 4 -/AGG Glu155del
(E155del)
0.0125 rs11509437 Forward: 5’-TCTAGGTGCCATCC TTG-3’
Reverse: 5’-TGATAGCTAGGAGAAATAA-3’
GSTO1 Exon 6 C®T Glu208Lys
(K208E)
0.0125 rs11509438 C___11309432_20
GSTO1 Exon6 A®C Thr217Asn
(T217N)
0.0000 rs15032 C___1174185_80
GSTO2 Exon2 5’UTR
(-183)
A®G
— 0.2032 rs2297235 C___3223142_1_
GSTO2 Exon5 A®G Asn142Asp
(N142D)
0.2467 rs156697 C___3223136_1_
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version 2.0, software. Each sample was verified visually
by examining the PCR curves generated to eliminate
false positives aberrant light emission.
RFLP for GSTO1 and GSTO2: The GSTO1 A140D
genotype was determined by PCR-RFLP. The primers
for PCR were 5’-AAA GTT GTT TCT TAA ACG TGC
C-3’ and 5’-AAG TGA CTT GGA AAG TGG GAA-3’.
The reaction was incubated at 95°C for 15 min and sub-
jected to 35 cycles of 94°C for 60 s, 55°C for 60 s, 72°C
for 60 s, and a final extension for 10 min at 72°C. The
PCR products were digested with Cac8 I (New England
Biolabs), and the products were separated on 3% agarose
gels. The genotypes were determined as follows: homo-
zygous wild type C/C: 243, 145, and 67 bp; heterozygous
C/A: 388, 243, 145, and 67 bp; homozygous variants A/
A: 388 and 67 bp.
Determination of GSTO2 N142D genotype by PCR-
RFLP: The primers for PCR were 5’-ACT GAG AAC
CGG AAC CAC AG-3’ and 5’-GTA CCT CTT CCA
GGT TG-3’. The reaction was incubated at 95°C for 10
min and subjected to 35 cycles of 95°C for 60 s, 62°C
for 60 s, and 72°C for 60 s, followed by a final extension
at 72°C for 10 min. The PCR product was digested with
MboI (New England Biolabs), and the products were
separated on 3% agarose gels. The genotypes were deter-
mined as followed: homozygous wild type A/A: 280 bp;
heterozygous A/G: 280, 231, and 49 bp; homozygous
variants G/G: 231 and 49 bp.
For the GSTO1 A140D and GSTO2 N142D poly-
morphisms, all the cancer specimens and 20% of the
non-cancerous specimens were repeated by RFLP-PCR.
The  statistics were about 0.88 and the samples with
discordant results were sent for DNA sequencing for
genotype validation. For GSTM1 and T1, all of the can-
cer samples and 20% of the non-cancer samples were
repeated; the samples with discordant results were
repeated until two same data were shown for the geno-
types. For other SNPs, 15% of the samples were run in
duplicate and all of the  statistics were > 0.94. All the
samples were relabeled for the experiments and the
researchers were blinded to individual identities and
results.
Statistical analysis
The outcome of primary interest was newly-diagnosed
UC (formerly urinary transitional cell carcinoma) during
the follow up. Individual follow-up person-years were
calculated from the entry date into the study to the date
of cancer diagnosis, death, or study end on Dec 31,
2007, whichever came first. Among 764 study subjects,
the incidence of the disease outcome was calculated and
the age-sex adjusted hazard ratio (HR) was estimated
using Cox’s proportional hazard model according to
putative risk factors including age at recruitment (< 49,
50-59, 60+years), sex, education (illiteracy, elementary
school, high school or more), cigarette smoking (yes or
no), alcohol drinking (yes or no) and CAE (0-9.9, 10.0-
19.9, 20+ mg/L*year).
Tests for Hardy-Weinberg equilibrium of each genetic
marker among non-cancer subjects were conducted on
observed and expected genotype frequencies using Pear-
son’s c
2 test with one degree of freedom. The SNPs
with variant frequencies greater than 10% were included
for further analysis. The incidence of UC was calculated
by the genotypes of selected markers. For GSTM1 and
GSTT1, genotypes were dichotomized into two cate-
gories (null and non-null genotypes). For GSTP1,
GSTO1, GSTO2, genotypes were categorized into three
groups (major allele homozygous, heterozygous, and
homozygous variant). Cox proportional hazard regres-
sion analyses were used to estimate HRs and 95% confi-
dence intervals (CIs) for associations between genotypes
of interest and outcome, controlling for the following
putative risk factors including age (continuous), gender,
educational level, and cigarette smoking. Linkage dise-
quilibrium was analyzed by calculating D’ values for
GSTO1 A140D, GSTO2 5’UTR(-183)A/G, and GSTO2
N142D. D’ is a coefficient of linkage disequilibrium and
can be estimated as (pABpab -p AbpaB)w h e r ep AB is a
fraction of gamete AB. |D’|v a l u e sr a n g e df r o m1 . 0
when two polymorphisms were maximally associated
and zero when they were randomly associated.
A stratified analysis by arsenic exposure was per-
formed to examine whether the association of the
selected markers with arsenic-induced UC depended on
exposure level. To maximize the differences between
two stratified groups and to avoid “zero” UC case
among the subjects with relatively low exposure level
and with heterozygous or homozygous variant genotype,
the sensitive analysis with various CAE cutoff points
was performed to monitor the optimal cutoff point for
stratified analyses. We conducted gene-exposure interac-
tion analyses using a regression model; the multivari-
able-adjusted HR was estimated for each group using
subjects with the wild homozygote and low arsenic
exposure as a reference. For the non-null and null geno-
types, an interaction term was created and a p value was
estimated by comparing the two models with or without
the interaction term. For three genotypes, two dummy
variables were created as interaction terms (heterozy-
gous*arsenic group, homozygous variant*arsenic group),
and a p value was estimated by comparing two models
with or without the two interaction variables. The etio-
logic fraction for the effects of the interaction, an indica-
tion of the “departure from additivity ([RR11-RR01-RR10
+RR00]/RR11), was calculated and the 95% CI was esti-
mated using the formula described by Walker [36]. If
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instead to calculate EF and 95%CI. All analyses were
performed with SAS statistical software (version 9.1.2,
SAS Institute Inc., Cary, NC, USA). The study was
approved by the ethics board of the institution prior to
starting the study and the informed consent was
obtained from all subjects.
Results
A total of 13,317 person-years were observed during the
18 years of follow-up, with a median period: 16.4 years.
By the end of 2007, a total of 41 newly-diagnosed UC
had occurred during the follow-up period, yielding an
incidence of 307.9 cancers per 100,000 person-years.
Table 2 shows the events and follow-up person-years
for UC by age at recruitment, sex, educational level,
cigarette smoking, alcohol drinking and CAE. Increased
UC incidence was found to be associated with older
people, being male and having low education level. Edu-
cation level was inversely associated with the risk of UC
in a dose-response manner. Cigarette smoking and alco-
hol drinking was not significantly associated with cancer
risk. The incidence rates of UC per 100,000 person-
years was 26.4, 207.2 and 835.1 for CAE < 10.0, 10.0 ≦
CAE < 20.0 and CAE ≥ 20.0, respectively. When com-
pared to the CAE < 10.0 group as the reference, the
HRs were 5.96 (95%CI, 0.72-49.03) and 19.31 (95%CI,
2.46-151.24) for the low to high exposure levels with a p
value 0.0003 for test for trend.
Linkage disequilibrium analysis showed that the
GSTO1 Asp140 allele was strongly linked with the
GSTO2 5’UTR(-183) G allele and the GSTO2 Asp142
allele (|D’|, 0.9039 and 0.9038, respectively. p <0 . 0 0 0 1
for both SNPs). The GSTO1 Glu155 deletion in exon
4 was strongly linked with the Lys 208 allele in exon
6. The incidences and age-sex-adjusted HRs for the
SNPs of interest and the GSTO1 A140D-O2 A(-183)
G-O2 N142D diplotype are shown in Table 3. The
GSTT1 null genotype was found to be significantly
associated with an increased cancer risk (HR, 1.91,
95% CI: 1.00-3.65, p = 0.05). The GSTO diplotype
AGG/AGG was potentially associated with increased
cancer risk, but the association was not statistically
significant.
Table 2 Univariate analysis of urothelial carcinoma (UC) risk among 764 cohort subjects by age at recruitment, sex,
education level, cigarette smoking, alcohol drinking and cumulative arsenic exposure
Risk factors Count(%) Follow-up person-years UC Crude incidence
(per 10
5)
Age- Sex adjusted
HR (95%CI)
Age at recruitment
a
< 50 390(51.1) 7251 11 151.7 ref
50-59 270(35.3) 4508 22 488.0 3.38(1.64-6.98)**
60+ 104(13.6) 1557 8 513.8 3.68(1.48-9.18)**
Sex
b
Male 336(44.0) 5716 20 349.9 ref
Female 428(56.0) 7601 21 276.3 0.77(0.42-1.43)
Education level
Illiteracy 256(33.5) 4270 22 515.2 ref
Elementary 363(47.5) 6386 18 281.9 0.64(0.32-1.25)
High school and above 145(19.0) 2662 1 37.6 0.11(0.01-0.83)*
Ptrend: 0.01
Cigarette smoking
No 595(77.9) 10535 33 313.2 ref
Yes 169(22.1) 2781 8 287.7 0.67(0.27-1.64)
Alcohol drinking
No 660(86.4) 11595 33 284.6 ref
Yes 104(13.6) 1721 8 464.8 1.40(0.58-3.35)
Cumulative arsenic exposure (mg/L*yr)
0-9.9 206(26.9) 3792 1 26.4 ref
10.0-19.9 188(24.6) 3379 7 207.2 5.96 (0.72-49.03)
20.0+ 183(23.9) 2874 24 835.1 19.31 (2.46-151.24))**
Unknown 187(24.6) 3271 9 275.1 7.11 (0.86-58.83)
Ptrend:0.0003
a: Adjusted for sex; b: Adjusted for age in a-year increment
UC: urothelial carcinoma; HR: hazard ratio; CI: confidence interval
* p < 0.05; **p < 0.01; ***p < 0.0001
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points of arsenic exposure level, it was consistently
shown that the gene effect of GSTT1 and GSTO1
A140D was largely confined to high cumulative arsenic
exposure (Additional file 1). When CAE cutoff point
was 20 mg/l*years, the significant association of both
GSTT1 and GSTO1 A140D with UC risk could be
observed.
Table 4 shows the stratified analysis of the association
between the SNPs and risk of UC according to CAE sta-
tus with cutoff point as 20 mg/l*years. Significant asso-
ciation of the GSTT1 null genotype with an increased
cancer risk was only observed among high exposure
group with CAE ≥ 20 (HR, 3.25, 95% CI, 1.20-8.80, p =
0.02). The subjects with both a high exposure level and
the homozygous variant of GSTO1 Asp140 had an
increased HR of 4.79 (95% CI, 1.03-22.39, p = 0.05),
with incidence rates of 3508.8 per 100,000. Analysis of
GSTO1/O2 showed that among the CAE ≥ 20 subjects,
the diplotype AGG/AGG had a significantly increased
cancer risk compared to CAA/CAA subjects with an
estimated HR of 4.91 (95% CI, 1.02-23.74, p =0 . 0 5 ) .N o
increased cancer risk for the AGG/AGG genotype was
observed among the subjects with CAE < 20.
The interaction analysis of GSTT1 and arsenic expo-
sure level on UC risk is shown in Figure 1. The subjects
with GSTT1 null genotype and high arsenic exposure
had a 4.1-fold higher risk of UC (HR, 4.08, 95% CI,
1.46-11.40, p < 0.01) when compared to the subjects
with low exposure and the GSTT1 non-null genotype.
The interaction was statistically significant in the multi-
plicative model and the etiologic fraction was 0.86. The
interaction analysis of the GSTO1/O2 diplotype and
arsenic exposure level on UC risk is shown in Figure 2.
The subjects with the GSTO AGG/AGG diplotype and
high arsenic exposure had a 34-fold higher cancer risk
(HR, 34.43, 95% CI, 5.03-235.74, p < 0.01) when com-
pared to the reference and the etiologic fraction was
estimated to be 0.80.
Discussion
Our study was designed to estimate gene effect together
with gene and arsenic exposure interaction on the risk
of urothelial carcinoma by long-term follow-up study. In
the present study, the dose-response relationship
between CAE and UC risk was consistent with our pre-
vious observations in southwestern and northeastern
Taiwan [11,12]. The protective role of education level
suggested that a low socioeconomic status was asso-
ciated with an increased risk of As-induced UC. Cigar-
ette smoking was not significantly associated with UC,
suggesting that tobacco use plays a relatively minor role
in urinary carcinogenesis in an area that has high expo-
sure to arsenic. We propose the possibility that people
who smoke in the arsenic-exposed area have a strong
tendency to develop lung cancers because of a signifi-
cant interaction between smoking and arsenic on lung
carcinogenesis [37]. Such a tendency may have the effect
of attenuating the association between smoking and UC.
Although urothelial cancer cases were limited in the
study, cancer cases among 363 subjects with GSTT1
null was twice as many as the cases among 368 subjects
with GSTT1 non-null and a significant association of
GSTT1null with UC could be observed with the adjust-
ment of cigarette smoking and potential confounding
factors. Moreover, the genetic effect of GSTT1 on can-
cer risk was largely confined to high arsenic level. The
interaction between GSTT1 and high exposure level was
statistically significant under the multiplicative model.
Table 3 Univariate analysis of urothelial carcinoma risk
by genotypes of GST superfamily
Urothelial carcinoma
No (%) Case no. HR (95% CI) P value
GSTM1
Non-null 312 (42.5) 18 ref
Null 422 (57.5) 23 0.94(0.51-1.74) 0.84
GSTT1
Non-null 368 (50.3) 14 ref
Null 363 (49.7) 27 1.91(1.00-3.65)* 0.05
GSTP1-105
AA 491 (64.8) 25 ref
AG 192 (25.3) 10 1.07(0.51-2.23) 0.86
GG 75 (9.9) 5 1.71(0.64-4.56) 0.29
AG+GG 267 (35.2) 15 1.21(0.64-2.31) 0.56
GSTO1-140
CC 521 (70.0) 27 ref
CA 199 (26.7) 9 0.81(0.38-1.73) 0.59
AA 24 (3.3) 2 2.11(0.50-8.99) 0.31
CA+AA 223 (30.0) 11 0.92(0.45-1.85) 0.80
GSTO2-(-183)
AA 487 (64.2) 26 ref
AG 234 (30.9) 11 0.73(0.36-1.48) 0.38
GG 37 (4.9) 4 2.58(0.88-7.52) 0.08
AG+GG 271 (35.8) 15 0.90(0.48-1.71) 0.75
GSTO2-142
AA 428 (56.6) 20 ref
AG 283 (37.4) 17 1.14(0.60-2.19) 0.69
GG 45 (6.0) 4 2.62(0.88-7.83) 0.08
AG+GG 328 (43.4) 21 1.28(0.69-2.37) 0.43
GSTO1(140)/O2(-183)/O2(142)
CAA/CAA 397 (53.8) 18 ref
CAA/AGG 163 (22.1) 7 0.83(0.34-1.98) 0.66
AGG/AGG 20 (2.7) 2 3.08(0.70-13.54) 0.13
Others 158 (21.4) 11 1.55(0.73-3.28) 0.25
HR: adjusted for age/gender/cigarette smoking/education level
HR: hazard ratio; CI: confidence interval
* p < 0.05; **p < 0.01; ***p < 0.0001
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Page 6 of 11These observations suggest that GSTT1 may have a sig-
nificant role in As-induced urothelial carcinogenesis,
especially among high exposure level. The current result
was inconsistent with the previous studies showing the
GSTT1 non-null genotype was associated with an
increased risk of As-induced skin lesions [38] and UC
[39]. The limited sample size without sufficient power
to detect true association may partly explain the discre-
pancies of these studies. The other possibility for these
discrepancies may due to markedly difference of expo-
sure level among these studies. We noticed the protec-
tive role of GSTT1 non-null was largely confined to the
individuals with cumulative arsenic exposure higher
than 20 mg/L*years in the present study. On the other
hand, the association of GSTT1 non-null with increased
bladder cancer risk was more confined to individuals
with relatively low level exposure (most study subjects
have consumed contaminated water with arsenic con-
centration less than 0.2 mg/L for less than 30 years).
These observations reveal the possibility that the effects
of GSTT1 polymorphism on susceptibility to arsenic-
induced urothelial carcinoma depend on arsenic expo-
sure level. The association between GSTs and UC with
regard to various arsenic exposure levels needs to be
further clarified.
The roles of GSTT1 in arsenic-induced carcinogenesis
remain unclear. The modulating effect of GSTs on arsenic
methylation has been explored in several studies. Our pre-
vious study on the northeast coast of Taiwan has shown
that the GSTT1 null genotype was associated with an
Table 4 Stratified analysis of urothelial carcinoma risk by genotypes of GSTM1, T1, P1, O1 and O2 according to
cumulative arsenic exposure
CAE < 20 mg/L*yr CAE ≧ 20 mg/L*yr
No Cs No. HR (95% CI) P
value
No Cs No. HR (95% CI) P value
GSTM1
Non-null 165 4 ref 70 10 ref
Null 211 4 0.69(0.17-2.81) 0.61 110 14 0.90(0.40-2.03) 0.79
GSTT1
Non-null 194 6 ref 76 5 ref
Null 180 2 0.27(0.05-1.37) 0.11 104 19 3.25(1.20-8.80)* 0.02
GSTP1-105
AA 262 7 ref 112 12 ref
AG 93 1 0.41(0.05-3.35) 0.41 47 7 1.41(0.55-3.62) 0.47
GG 36 0 0.00 0.99 22 4 1.76(0.51-5.73) 0.35
AG+GG 129 1 0.33(0.04-2.66) 0.30 69 11 1.52(0.66-3.48) 0.33
GSTO1-140
CC 264 6 ref 126 16 ref
CA 106 1 0.32(0.04-2.73) 0.30 47 4 0.70(0.23-2.10) 0.52
AA 17 0 0.00 0.99 4 2 4.79(1.03-22.39)* 0.05
CA+AA 123 1 0.30(0.04-2.49) 0.26 51 6 0.97(0.37-2.50) 0.94
GSTO2-(-183)
AA 247 6 ref 115 16 ref
AG 119 1 0.23(0.03-2.02) 0.19 61 6 0.71(0.28-1.84) 0.48
GG 26 1 2.04(0.23-17.88) 0.52 6 2 2.90(0.61-13.66) 0.18
AG+GG 145 2 0.43(0.09-2.21) 0.32 67 8 0.87(0.37-2.05) 0.74
GSTO2-142
AA 218 4 ref 100 13 ref
AG 145 4 1.17(0.28-4.80) 0.83 71 8 0.88(0.37-2.14) 0.78
GG 29 0 0.00 0.99 11 3 2.53(0.71-8.99) 0.15
AG+GG 174 4 1.05(0.26-4.30) 0.94 82 11 1.08(0.48-2.41) 0.86
GSTO1(140)/O2(-183)/O2(142)
CAA/CAA 205 3 ref 94 12 ref
CAA/AGG 89 0 0.00 0.99 41 4 0.79(0.25-2.49) 0.69
AGG/AGG 15 0 0.00 1.00 4 2 4.91(1.02-23.74)* 0.05
Others 77 4 3.45(0.75-15.78) 0.11 38 4 0.85(0.27-2.65) 0.78
HR adjusted for age/gender/cigarette smoking/education level * p < 0.05; **p < 0.01; ***p < 0.0001
GST: glutathione S-transferase; CAE: cumulative arsenic exposure; HR: hazard ratio; CI: confidence interval;
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Page 7 of 11elevated percentage of dimethylarsonous acid (DMA) in
urine [40]. By contrast, the study in Argentina showed
that the GSTT1 null was associated with lower percentage
of DMA [28]. Modification effect of the GSTT1 null on %
MMA and %DMA was also observed in that study.
Although these studies show inconsistent results for the
association between GSTs and urinary arsenic metabolite
pattern, the findings indicate that the GSTT1is possibly
responsible for a part of interindividual variation in arsenic
metabolism. From current knowledge the GSTT1 does not
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Figure 1 Interaction analysis between arsenic exposure level and GSTT1 genotype on UC risk.
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Page 8 of 11catalyze the reactions of arsenic methylation directly.
Instead, GSTT1 may involve in arsenic methylation by an
indirect way, for example, by depletion the glutathione
(GSH) level. GSH is required for arsenic metabolism such
as iAs(V) or MMA(V) reduction [36,41]. Depletion of
GSH might cause decreased efficiency of arsenic methyla-
t i o n .T h eG S T T 1n u l lm a yh a v eap r o t e c t i v er o l eo n
urothelial carcinogenesis if this enzyme can quickly
deplete the GSH.
In addition to the possible roles of GSTs in arsenic bio-
transformation, GSTs are also phase II metabolic enzymes
that are involved in detoxification of the xenobiotics by
glutathione conjugation. The evidence generally supports
the modulating effect of GSTM1 and GSTT1 polymorph-
isms on cancers closely-related to chemical exposure,
including bladder cancer [42,43]. GSTs may prevent DNA
damage from endogenously-formed oxidative stress or
environmentally-exposed carcinogens [44-46]. There is
considerable evidence that reactive oxygen species (ROS)
are involved in the genotoxicity of arsenical compounds
[47,48]. Our previous study in Northeastern Taiwan
showed that the concentration of reactive oxidants of
plasma was positively correlated with arsenic concentra-
tion in whole blood among arsenic-exposed people [49].
These phase II enzymes, perhaps GSTT1, possibly play an
important role to detoxify arsenic-induced ROS. Up to
now the direct reactions of GSTs toward arsenic-induced
ROS have yet been reported and the relations between
GSTs, arsenic-induced ROS and DNA damage need to be
further addressed.
For the overall study subjects without considering
arsenic exposure level, GSTO1/O2 was not associated
with urothelial carcinoma, suggesting the limited role of
GSTOs for urothelial carcinogenesis. However, among
high As-exposed subjects with 75% UC cases diagnosed
in this subgroup (24 among a total of 32 UC cases with
known exposure levels), a significant association
between GSTO polymorphism and UC was observed. In
this highly-exposed group, strikingly high UC incidence
was observed (3500 per 100,000) among people with
GSTO1/O2 AGG/AGG diplotype. This observation sug-
gests a possible role of GSTOs in individual susceptibil-
ity to UC especially at a high exposure level. Our result
also supports the previous studies showing the modifica-
tion effect of GSTOs on As-induced health effects
[20,33]. For examples, GSTO2 A424G and A-183G
homovariant was associated with a 1.6-fold and a 2.4-
fold UC risk, respectively in one hospital-based case-
control study [33]. A study in Bangladesh also showed
an joint effect of arsenic exposure with GSTOs on As-
induced skin lesions [20]. Based on these observations
GSTOs might be a significant modifier for arsenic-
induced carcinogenesis. However, the magnitude of the
association between GSTOs polymorphisms and As-
induced cancers across different exposure levels has not
been well-evaluated. Further studies with larger sample
size, precise exposure assessment and large variation of
exposure level are needed to draw these issues.
Both GSTO1 and GSTO2 are involved in arsenic
methylation catalyzing the reduction of pentavalent
arsenicals to trivalent arsenicals. Different GSTO poly-
morphisms may be of different capacity of arsenic meta-
bolism, which may explain for variation susceptibility to
arsenic. Inefficient methylation of arsenic has been
reported to be associated with arsenic-induced skin
lesions, skin cancers, bladder cancers and cardiovascular
diseases [17-21]. Our previous study indicated that
GSTO2 N142D GG genotype was associated with a
higher percentage of iAs [31]. Two studies displayed
that GSTO1 E155del was associated with markedly-
changed percentage of iAs when compared to the wild
homotype [32,50]. These studies suggest the effects of
GSTOs polymorphisms on percentage of iAs. However,
the association of GSTO1 with urinary arsenic metabo-
lite pattern remains inconclusive because several studies
did not show a significant association [28-30]. The
inconsistent results among these studies might be due
to very little concern for potential confounding factors
such as ethnicity, nutritional status, As exposure level
and other environmental factors. Better control of these
confounding factors in further studies helps evaluation
of real effect of GSTOs on arsenic methylation. In addi-
tion to MMA(V)/DMA(V) reductase activities, GSTOs
also exhibits high thioltransferase activity as well as
dehydroascorbate reductase activity and thus the
enzymes could participate in intracellular thiol homeo-
static reactions and antioxidant ascorbate recycling,
respectively. Such enzyme activities reveal another possi-
bility whereby changes in thioltransferase activity as well
as ascorbate reductase activity may explain individual
susceptibility to arsenic-induced health effects.
The present study had several limitations. Firstly, the
small sample size with a limited number of cancer cases
is a major limitation of this study. Based on such limited
case numbers, a significant association of genetic mar-
kers with cancer risk is hard to reach after a Bonferroni
correction for multiple comparisons. For this concern,
we performed permutation tests to obtain the empirical
p-value to overcome the size limitation and multiple
testing issues (data not shown). Permutation is a non-
parametric test and the empirical p-value can be
obtained by calculating all possible test statistic under
random rearrangements of the disease status on the
study subjects [51]. The permutation tests performed for
this study revealed the same results with that obtained
by traditional statistical analysis, giving additional sup-
port for such gene-disease association. A second limita-
tion is that about one-fourth of individual’sC A Ei s
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Page 9 of 11missing, which decreases the power for the estimate of
gene-environment interaction. Finally, the estimates of
exposure status from questionnaires are subject to recall
bias. However, the recall bias is considered to be non-
differential between the cases and non-cases and thus
the HRs should be underestimated. Notwithstanding
these limitations, it is clear that this study was able to
estimate the genetic effects of GSTT1 and GSTOs on
the risk of UC, and, furthermore, the interactions
between polymorphisms of such genes and high-level
arsenic exposure can still be identified.
Conclusion
We estimated the gene effects of members of GST super-
family on arsenic-induced urothelial carcinoma by long-
term follow-up study in southwestern Taiwan. The
results reveal the fact that the GSTs do not play a critical
role in arsenic-induced urothelial carcinogenesis. How-
ever, the present data provide evidence that the effects of
GSTT1 and GSTOs on arsenic-induced UC are possibly
confined to high exposure level, where the subjects had
UC risk almost twenty-fold higher than that of low expo-
sure level. These observations are helpful for the identifi-
cation of high risk group of urothelial carcinoma among
arsenic-exposed people. In the future, the studies with a
larger sample size, longer follow-up periods, markedly
variation of exposure level as well as better control of
confounding factors are needed to estimate single gene,
gene-gene and gene-environmental interaction on the
risk of adverse arsenic-induced health effects.
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